logo
Plus   Neg
Share
Email

Precision Drilling Updates 2019 Capital Expenditure Plan - Quick Facts

Precision Drilling Corp. (PD.TO,PDS) lowered its 2019 capital expenditure plan following the completion of Kuwait new build project. The company said it remains firmly committed to its deleveraging strategy and reaffirmed debt reduction target for 2019, and for long-term. Also, Precision Drilling Corp. plans to implement a normal course issuer bid for a portion of its common shares.

For 2019, Precision reduced capital expenditure plan to approximately C$144 million, from previously stated budget of C$169 million.

For the year-to-date period, the company's debt reduction is at C$136 million, reaffirming its targeted debt reduction for 2019, and the long-term targeted range of C$400 million to C$600 million by the end of 2021.

For 2020, the company projects: capital expenditure range of C$60 million to C$80 million and debt reduction in a range of C$100 million to C$150 million.

Under a NCIB, the company plans to purchase up to 10% of the public float over a period of twelve months.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Deutsche Post DHL Group were gaining around 5 percent in the morning trading in Germany after the package delivery and supply chain management company reported Tuesday significantly higher profit in its third quarter. Looking ahead, the company anticipates a traditionally strong holiday season in the fourth quarter. The company also confirmed its annual earnings outlook. A New York regulator has launched an investigation into the credit card practices of Goldman Sachs Group Inc. for alleged gender discrimination in determining limits for Apple's new credit card, which is administered by Goldman Sachs. The Apple Card, Apple's first credit card, was introduced by the tech giant in March this year in partnership with Goldman Sachs and Mastercard. The U.S. Food and Drug Administration approved the first therapy for patients with a rare inherited blood disorder called beta thalassemia. Celegene's Reblozyl is also the first and only FDA-approved erythroid maturation agent, a new class of therapy for such patients. The regulator approved Reblozyl for treating anemia in adult patients with beta thalassemia who require regular RBC transfusions.
RELATED NEWS
Follow RTT
>